1. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. (November 2016) Authors: Kahl, L; Patel, J; Layton, M; Binks, M; Hicks, K; Leon, G; Hachulla, E; Machado, D; Staumont-Sallé, D; Dickson, M; Condreay, L; Schifano, L; Zamuner, S; van Vollenhoven, R F Journal: Lupus Issue: Volume 25:Number 13(2016) Page Start: 1420 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. (4th February 2015) Authors: Sahota, T; Berges, A; Barton, S; Cookson, L; Zamuner, S; Richards, D Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 4:Number 2(2015:Feb.) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. (4th February 2015) Authors: Sahota, T; Berges, A; Barton, S; Cookson, L; Zamuner, S; Richards, D Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 4:Number 2(2015:Feb.) Page Start: 116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗